drugset / Trial / NCT04662294
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases
Timeline
- Start
- 2021-11-18
- Primary completion
- 2024-01-15
- Completion
- 2027-01-15
Publications
- Dewulf J, Flieswasser T, Delahaye T, Vangestel C, Miranda A, de Haard H, Jacobs J, Smits E, Van den Wyngaert T, Elvas F. Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models. EJNMMI Radiopharm Chem. 2023 Apr 24;8(1):8. doi: 10.1186/s41181-023-00194-3.
- Golubovskaya V. CAR-T Cells Targeting Immune Checkpoint Pathway Players. Front Biosci (Landmark Ed). 2022 Apr 2;27(4):121. doi: 10.31083/j.fbl2704121.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD70 CAR-T cells | Cell therapy | — | Intravenous |